Clinical Trial Update: Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Completed Phase 2 trial evaluating camrelizumab combined with apatinib as perioperative treatment for resectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Resectable Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED